Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29621110 | 1.00 | GAA (0.58) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL22925607 | 0.77 | ROCK2 (0.43) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL29620980 | 0.77 | NOTUM (0.58) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL17193258 | 0.77 | NOTUM (0.58) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL9284896 | 0.77 | LMNA (0.58) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL3388292 | 0.77 | MAP4K4 (0.47) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL30753615 | 0.77 | MAP4K4 (0.47) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL28500936 | 0.74 | MEN1 (0.53) | GAAMEN1KMT2AROCK2PTK2 | |
| SCHEMBL102644 | 0.74 | GAA (1.00) | GAAMEN1KMT2APTK2NOTUM | |
| SCHEMBL40864 | 0.73 | KDM4E (0.46) | MEN1KMT2AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676547-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024186584-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151158-A1 | ISOXAZOLINES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-1289984-A4 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM CO LTD (KR) | 2004-11-24 | — | — | EP | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
| CN-1433413-A | Oxazolidinone derivatives and process for their preparation | DONG A PHARM CO LTD (KR) | 2003-07-30 | — | — | CN | disclosed |
| EP-1289984-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | Dong A Pharmaceutical Co. Ltd. (KR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001094342-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM. CO., LTD. (KR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | GAA 2106/4885MEN1 3445/4885KMT2A 3579/4885 |
| US-20130023526-A1 | Isoxazolines as Therapeutic Agents | CYP3A7, CYP11B2, CYP11B1 | GAA 1651/4885MEN1 2102/4885KMT2A 3753/4885 |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | GAA 59/4885MEN1 1826/4885KMT2A 3735/4885 |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | GAA 544/4885MEN1 3707/4885KMT2A 3560/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | GAA 2022/4885MEN1 798/4885KMT2A 1823/4885 |
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | GAA 59/4885MEN1 1826/4885KMT2A 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.